Keyword: PRA Health Sciences
PRA will buy health data and analytics expert Symphony Health for $530 million up front as it reports 16% second-quarter service revenue growth.
Takeda inked a multiyear, $170 million-per-program drug discovery partnership with Schrödinger.
Ex-Novo exec Høiland became Radius' CEO, ex-Sanofi Genzyme CEO Meeker joined Trevi as chairman, Myovant tapped four execs with Big Pharma experience.
DelMar is advancing its first-in-class brain cancer med dianhydrogalactitol (VAL-083) into phase 3, and it has recruited PRA Health Sciences to conduct that pivotal study.
U.K.-based CRO Chiltern has put itself up for sale as it continues the bullish M&A run for contract research groups that has seen a host of deals, JVs and mergers over the last 2 years.
Takeda is nearing the final stages of a joint venture with PRA Health Sciences, the product of an expansion of their clinical development partnership in Japan announced in February.
A bipartisan bill that plans to allow a tax credit for expenses of contracted research—often done by CROs—has been introduced in the House of Representatives.